Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
about
Mechanisms of fibrin polymerization and clinical implicationsRole of Platelet-Derived Microvesicles As Crosstalk Mediators in Atherothrombosis and Future Pharmacology Targets: A Link between Inflammation, Atherosclerosis, and ThrombosisEffect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trialsImpaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetesAll-trans-retinoic acid ameliorated high fat diet-induced atherosclerosis in rabbits by inhibiting platelet activation and inflammation.Whole-blood tissue factor procoagulant activity is elevated in type 1 diabetes: effects of hyperglycemia and hyperinsulinemia.Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots.Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application.Microvesicles and diabetic complications--novel mediators, potential biomarkers and therapeutic targets.Predictors of and survival after incident stroke in type 1 diabetesMicroparticles as novel biomarkers and therapeutic targets in coronary heart disease.Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.The association of hematologic inflammatory markers with atherogenic index in type 2 diabetic retinopathy patientsCell-derived microparticles in atherosclerosis: biomarkers and targets for pharmacological modulation?Anti-inflammatory therapy in type 1 diabetes.Fibrin(ogen) and thrombotic disease.Risks and benefits of statin use in young people with type 1 diabetes.The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse.Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease.Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent.Hypertriglyceridemia in Diabetes Mellitus: Implications for Pediatric Care.Glycated LDL-C and glycated HDL-C in association with adiposity, blood and atherogenicity indices in metabolic syndrome patients with and without prediabetesIs Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
P2860
Q26865281-F2756C6E-5EDD-4EF2-A840-48CA67E63C01Q28069254-7E1E4CC1-AD4E-43FD-837F-C32662992C0AQ28483807-EBFAC8AF-E9CF-4785-8C40-39864AEF90A8Q34792852-7AB178C5-646E-4C85-B6CC-E5916B1CF527Q35688330-52CEC55F-0880-40F3-AB21-587183647D1BQ35830449-4C437008-D7B0-41E8-A5E3-5FFA477E6E7AQ35976478-F2C3C607-89A4-480A-8CC9-BDD4451D3961Q36346156-CF31A3EF-7756-4A64-AF62-6CACFCBA7501Q36482113-B418C4EB-0223-4970-9109-6DF3569E06FDQ36745194-C670EB55-8637-4915-BCD4-ECD30726F0F9Q36793264-C080183D-3DDB-464A-AE17-E913588E950CQ36816361-3C022F52-3E27-4397-93BE-EE96E7CF2504Q36986116-6473E7C0-7FD6-4EF5-BFAA-0D8A9E96A031Q37276729-43B9356B-D7CB-4B50-9B71-EF889E7CC3EBQ37295504-2D1AD049-D284-4737-8445-0426B604E9DCQ38025979-BC994927-E301-4384-8579-974BD7238BEEQ38117741-24383400-560D-4772-9C16-CD45040B5E3AQ38209424-A7D1F38D-07E6-4231-8878-AC7306B20998Q47159100-8A07C8E9-C5BA-4234-BEBB-D687CED31708Q49741768-13EA4AB3-2AED-4448-A7D8-D7D3F0A96968Q52915225-8973B089-FEDD-4BEF-8FF2-325E47DED7DFQ54450140-18EEA516-4527-463E-B4EE-8FF92ABD798FQ55176268-D9F67D48-AB1B-47CF-B8DA-D8F3C9864C17Q57495457-762DB7B2-9334-4167-BF03-4B6BE2617344Q58698213-471C1E3E-9154-46C8-9C7D-8BFF4A17CC18
P2860
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@en
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@nl
type
label
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@en
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@nl
prefLabel
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@en
Atorvastatin has antithromboti ...... e 1 diabetes and dyslipidemia.
@nl
P2093
P1433
P1476
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia
@en
P2093
Aleksandra Antovic
Gun Jörneskog
N Håkan Wallén
Per-Eric Lins
Peter Henriksson
Sara Tehrani
Ulf Adamson
P304
P356
10.1016/J.THROMRES.2010.05.023
P577
2010-07-15T00:00:00Z